DMID conducts and supports research to find new and improved ways to diagnose, treat and prevent virtually all human infectious diseases except HIV. In addition to grant support provided for investigator-initiated clinical trials, DMID supports clinical trials through the Infectious Diseases Clinical Research Consortium clinical trials network, the Early-Phase Clinical Trial Units, and pathogen-specific clinical trial networks such as the Antibacterial Resistance Leadership Group (ARLG) that focus on specific subsets of microbial pathogens. Consultation with relevant DMID staff is strongly encouraged to help investigators identify the best mechanism to fit their clinical trial needs.
Early-Phase Clinical Trial Units (EPCTU)
The Early Phase Clinical Trial Units (EPCTUs) support the design, development, implementation, and conduct of Phase 0 to Phase 2 clinical trials, including proof-of-concept studies in healthy, special, and disease-specific populations, against viral, bacterial, parasitic, and fungal pathogens and emerging and re-emerging infectious diseases. The EPCTUs evaluate candidate products from the preclinical and early product development programs of DMID, as well as from external research partners.
Infectious Diseases Clinical Research Consortium (IDCRC)
DMID’s Infectious Diseases Clinical Research Consortium (IDCRC) is a clinical trials network that conducts Phase 1 through Phase 4 vaccine and treatment trials, including clinical studies in collaboration with industry partners. IDCRC is a ready resource to help DMID respond quickly to public health emergencies, including COVID-19. IDCRC focuses on viral, bacterial, parasitic, and fungal pathogens and emerging and re-emerging infectious diseases.
Contact Your Program Officer To Discuss Scientific Services
Contact DMID staff for more information about scientific services.